Dupilumab has been demonstrated to be an effective treatment for patients with moderate-to-severe atopic dermatitis (AD) in clinical trials. However, evidence of real-world experience with dupilumab in a broader population is limited to date.
Use of Dupilumab for 543 Adult Patients with Moderate-To-Severe Atopic Dermatitis: A Multicenter, Retrospective Study
Rongioletti, FMembro del Collaboration Group
;Piras, VMembro del Collaboration Group
;
2022-01-01
Abstract
Dupilumab has been demonstrated to be an effective treatment for patients with moderate-to-severe atopic dermatitis (AD) in clinical trials. However, evidence of real-world experience with dupilumab in a broader population is limited to date.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
dupilumab rongio 2020.pdf
Solo gestori archivio
Tipologia:
versione post-print (AAM)
Dimensione
800.94 kB
Formato
Adobe PDF
|
800.94 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
